Cancer prevention and interception: A new era for chemopreventive approaches

Adriana Albini, Andrea DeCensi, F. Cavalli, Alberto Costa

Research output: Contribution to journalArticle

Abstract

At several recent, internationally attended scientific meetings, including the American Association for Cancer Research (AACR)'s "Shaping the Future of Cancer Prevention: A Roadmap for Integrative Cancer Science and Public Health" summit in Leesburg (VA) and the AACR Annual Meeting in New Orleans, the focus on cancer prevention to reduce cancer-related deaths was extensively discussed with renewed attention and emphasis. Cancer prevention should be actively proposed even to healthy individuals, and not just to individuals with high cancer risk. We discuss evaluation of a high cancer risk versus the relatively low risk for side effects of chemopreventive agents. The concept of cancer interception, which is halting transformed cells from becoming malignant cancers, should be adopted for cancer prevention. Potential prevention/interception actions include adopting healthy life style and avoiding carcinogens, repressing inflammation and pathologic angiogenesis, controlling metabolism, correcting insulin resistance and other metabolic alterations. Current drugs with limited toxicity can be repurposed to reduce cancer incidence. Aspirin is now being recommended for the prevention of colorectal cancer and it prevents other neoplasms as well. Metformin and b-blockers could be valuable for reducing pancreatic and breast cancer onset. On the basis of the evaluation of cancer risk, we here call for personalized approaches for cancer prevention and preventive interception and we envisage a list of measures and potential guidelines for preventive and interceptive strategies to reduce cancer burden. Investment into translational research to bring these approaches into public health policies and in the clinic is urgently needed.

Original languageEnglish
Pages (from-to)4322-4327
Number of pages6
JournalClinical Cancer Research
Volume22
Issue number17
DOIs
Publication statusPublished - Sep 1 2016

Fingerprint

Neoplasms
Public Health
Pathologic Neovascularization
Translational Medical Research
Metformin
Public Policy
Health Policy
Pancreatic Neoplasms
Carcinogens
Aspirin
Insulin Resistance
Colorectal Neoplasms
Guidelines
Breast Neoplasms
Inflammation
Incidence
Research
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Cancer prevention and interception : A new era for chemopreventive approaches. / Albini, Adriana; DeCensi, Andrea; Cavalli, F.; Costa, Alberto.

In: Clinical Cancer Research, Vol. 22, No. 17, 01.09.2016, p. 4322-4327.

Research output: Contribution to journalArticle

Albini, Adriana ; DeCensi, Andrea ; Cavalli, F. ; Costa, Alberto. / Cancer prevention and interception : A new era for chemopreventive approaches. In: Clinical Cancer Research. 2016 ; Vol. 22, No. 17. pp. 4322-4327.
@article{3cbc2bfd19c64d5eaa3a42f3cc58ba94,
title = "Cancer prevention and interception: A new era for chemopreventive approaches",
abstract = "At several recent, internationally attended scientific meetings, including the American Association for Cancer Research (AACR)'s {"}Shaping the Future of Cancer Prevention: A Roadmap for Integrative Cancer Science and Public Health{"} summit in Leesburg (VA) and the AACR Annual Meeting in New Orleans, the focus on cancer prevention to reduce cancer-related deaths was extensively discussed with renewed attention and emphasis. Cancer prevention should be actively proposed even to healthy individuals, and not just to individuals with high cancer risk. We discuss evaluation of a high cancer risk versus the relatively low risk for side effects of chemopreventive agents. The concept of cancer interception, which is halting transformed cells from becoming malignant cancers, should be adopted for cancer prevention. Potential prevention/interception actions include adopting healthy life style and avoiding carcinogens, repressing inflammation and pathologic angiogenesis, controlling metabolism, correcting insulin resistance and other metabolic alterations. Current drugs with limited toxicity can be repurposed to reduce cancer incidence. Aspirin is now being recommended for the prevention of colorectal cancer and it prevents other neoplasms as well. Metformin and b-blockers could be valuable for reducing pancreatic and breast cancer onset. On the basis of the evaluation of cancer risk, we here call for personalized approaches for cancer prevention and preventive interception and we envisage a list of measures and potential guidelines for preventive and interceptive strategies to reduce cancer burden. Investment into translational research to bring these approaches into public health policies and in the clinic is urgently needed.",
author = "Adriana Albini and Andrea DeCensi and F. Cavalli and Alberto Costa",
year = "2016",
month = "9",
day = "1",
doi = "10.1158/1078-0432.CCR-16-0695",
language = "English",
volume = "22",
pages = "4322--4327",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "17",

}

TY - JOUR

T1 - Cancer prevention and interception

T2 - A new era for chemopreventive approaches

AU - Albini, Adriana

AU - DeCensi, Andrea

AU - Cavalli, F.

AU - Costa, Alberto

PY - 2016/9/1

Y1 - 2016/9/1

N2 - At several recent, internationally attended scientific meetings, including the American Association for Cancer Research (AACR)'s "Shaping the Future of Cancer Prevention: A Roadmap for Integrative Cancer Science and Public Health" summit in Leesburg (VA) and the AACR Annual Meeting in New Orleans, the focus on cancer prevention to reduce cancer-related deaths was extensively discussed with renewed attention and emphasis. Cancer prevention should be actively proposed even to healthy individuals, and not just to individuals with high cancer risk. We discuss evaluation of a high cancer risk versus the relatively low risk for side effects of chemopreventive agents. The concept of cancer interception, which is halting transformed cells from becoming malignant cancers, should be adopted for cancer prevention. Potential prevention/interception actions include adopting healthy life style and avoiding carcinogens, repressing inflammation and pathologic angiogenesis, controlling metabolism, correcting insulin resistance and other metabolic alterations. Current drugs with limited toxicity can be repurposed to reduce cancer incidence. Aspirin is now being recommended for the prevention of colorectal cancer and it prevents other neoplasms as well. Metformin and b-blockers could be valuable for reducing pancreatic and breast cancer onset. On the basis of the evaluation of cancer risk, we here call for personalized approaches for cancer prevention and preventive interception and we envisage a list of measures and potential guidelines for preventive and interceptive strategies to reduce cancer burden. Investment into translational research to bring these approaches into public health policies and in the clinic is urgently needed.

AB - At several recent, internationally attended scientific meetings, including the American Association for Cancer Research (AACR)'s "Shaping the Future of Cancer Prevention: A Roadmap for Integrative Cancer Science and Public Health" summit in Leesburg (VA) and the AACR Annual Meeting in New Orleans, the focus on cancer prevention to reduce cancer-related deaths was extensively discussed with renewed attention and emphasis. Cancer prevention should be actively proposed even to healthy individuals, and not just to individuals with high cancer risk. We discuss evaluation of a high cancer risk versus the relatively low risk for side effects of chemopreventive agents. The concept of cancer interception, which is halting transformed cells from becoming malignant cancers, should be adopted for cancer prevention. Potential prevention/interception actions include adopting healthy life style and avoiding carcinogens, repressing inflammation and pathologic angiogenesis, controlling metabolism, correcting insulin resistance and other metabolic alterations. Current drugs with limited toxicity can be repurposed to reduce cancer incidence. Aspirin is now being recommended for the prevention of colorectal cancer and it prevents other neoplasms as well. Metformin and b-blockers could be valuable for reducing pancreatic and breast cancer onset. On the basis of the evaluation of cancer risk, we here call for personalized approaches for cancer prevention and preventive interception and we envisage a list of measures and potential guidelines for preventive and interceptive strategies to reduce cancer burden. Investment into translational research to bring these approaches into public health policies and in the clinic is urgently needed.

UR - http://www.scopus.com/inward/record.url?scp=84988632717&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988632717&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-16-0695

DO - 10.1158/1078-0432.CCR-16-0695

M3 - Article

VL - 22

SP - 4322

EP - 4327

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 17

ER -